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Summary: The pre-analytical, analytical and biological sources of variation were estimated for serum lipo-
protein(a) concentrations, as measured with a new commercially available procedure. There were no significant
differences between the concentrations of lipoprotein(a) measured in EDTA plasma and serum. The analyte
is stable in specimens stored for up to two weeks in the refrigerator, or up to three months at —20 °C. Fasting
is not essential before the lipoprotein(a) determination. Data on analytical (between-run coefficient of variation
< 15.7%), within-subject (8.6%) and between-subject variation (85.8%) were used to calculate the analytical
goal for imprecision (< 4.3%), the critical difference between serial values from an individual that represents
a significant change (36.3%), the number of specimens which should be collected to estimate the homeostatic
value for an individual to within + 5% (26), and to establish the marked individuality of lipoprotein(a)
(index of individuality, 0.1).
Introduction
Hyperlipidaemia is now an established major reason
for the development of coronary artery disease. Con-
siderable attention has been focussed on levels of low
(LDL) and high (HDL) density lipoproteins and the
apolipoproteins as risk factor determinants (1). Re-
cently, there has been a considerable resurgence of
interest in lipoprotein(a), since there is evidence that
the level of circulating lipoprotein(a) represents an
independent risk factor for premature coronary artery
disease, stroke, and development of atherosclerotic
lesions, with possibly greater predictive potential than
the other lipoprotein traits (2). The awareness of the
striking correlation between atherosclerosis and con-
centration of lipoprotein(a) in serum prompted the
development of several different assays for lipopro-
tein(a) determination (3). Specific antibodies are now
commercially available and lipoprotein(a) can be de-
tected and quantified routinely in any laboratory.
According to Cooper et al. (4), standardization of
measurements of lipoproteins requires recognition of
the pre-analytical sources of variation, the use of
preventive measures to control those variations, and
a choice of final conditions that minimize sample-
related sources of variation. Fräser et al. advocated
that data on analytical and biological variation, in
addition to pre-analytical variability, should be gen-
erated early in the evolution of a new test, i. e. lipo-
protein(a), to derive the information necessary for
assessing desirable performance characteristics or an-
alytical goals (5), the utility of the conventional pop-
ulation-based reference interval (6), and the difference
required for a change in serial results in an individual
to be significant (7). Furthermore, if a laboratory test
is to be used to screen the population, the number of
analyses required to assess the homeostatic value for
an individual should be determined. The purpose of
the present study was to obtain data on these various
sources of variation of lipoprotein(a) concentration
in patient samples, in order to obtain a complete
picture of all the possible components of variability
influencing this biochemical test. In particular, defin-
itive information on the biological variation of lipo-
protein(a) is so far not available, a fact that may seem
surprising when one considers the many reports on
serum lipoprotein(a) as a risk factor for premature
coronary artery disease and development of athero-
sclerosis.
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Materials and Methods
Procedures
Lipoprotein(a) was determined immunometrically as previously
described (8) using the Macra Lp(a) kit assay (Terumo Medical
Corp., Elkton, MD 21921, USA). This assay is based on the
use of a monoclonal antibody (1D1) raised against the kringle
IV domains of apolipoprotein(a) (solid phase), and a polyclonal
antibody raised against lipoprotein(a) and conjugated with per-
oxidase. The minimal detectable lipoprotein(a) concentration
was estimated to be 1.5 mg/1 (8). The immunoblotting technique
for phenotyping lipoprotein(a) was performed according to
Molinari et al. (9). Briefly, after reduction of the serum samples,
the apolipoprotein(a) isoforms were separated electrophoreti-
cally in a 4—15% polyacrylamide gel gradient using a com-
mercially available system (PhastSystem, Pharmacia, Uppsala,
Sweden). The separated proteins were transferred to nitrocel-
lulose membranes where they were fixed with a polyclonal anti-
human lipoprotein(a) serum from sheep (Immuno AG, Wien,
Austria). After removal of the unbound proteins by washing
and blocking of unreacted sites, an alkaline phosphatase-con-
jugated rabbit anti-sheep IgG (Chemicon International, Inc.,
El Segundo, CA 90245, USA) was used as the second antibody.
The complex was developed with the substrate (5-bromo-5-
chloro-3-indoxylphosphate) and the chromogen (nitroblue tet-
razolium) to visualize the bands. A lipoprotein(a) phenotyping
standard purchased from Immuno AG was run on each gel as
a reference.
Effect of anticoagulant
For preparing plasma specimens for lipoprotein measurement,
EDTA is usually the preferred anticoagulant. To investigate the
influence of sample type on the lipoprotein(a) concentration,
we collected serum and plasma EDTA dipotassium salt (2.5
mmol/1) specimens from 17 laboratory workers. Lipoprotein(a)
was analysed simultaneously in serum or plasma after centrif-
ugation at 4000 g for 15 minutes at 4 °C
Effect of storage
For a preliminary determination of the stability of lipopro-
tein(a) in serum, a sample containing 200 mg/1 lipoprotein(a)
was divided in aliquots of 100 μΐ in capped plastic tubing
segments, then kept at 4 °C and at —20 °C without the addition
of any preservative. Aliquots were assayed in quadruplicate
every other day for two weeks, and subsequently once a week
for three months (only for frozen specimen), and the signifi-
cance of the difference from the original value was tested. Later,
to further examine the longer-term effects of storage on lipo-
protein(a) isoform pattern, four serum samples with different
lipoprotein(a) phenotypes (apo(a) S2, S3, and S4 homozygotes
and apo(a) S2/S3 heterozygote according to the nomenclature
of Utermann (10)) were divided into aliquots, which were stored
at —20 °C for one, two, and three months, and assayed after
thawing for lipoprotein(a) concentration and isoform pattern.
Differences between lipoprotein(a) concentration at different
times were analysed by a matched t-test.
Effect of fasting
Fifteen subjects were studied: 12 females and 3 males, ages
23—73 years. All were in good health and received no medi-
cation. All had serum concentrations of lipoprotein(a) that were
above the lower limit of detection of the method. In the morn-
ing, after 12 hours fasting, 5 ml blood was drawn from the arm
vein of each subject, in order to establish baseline values. Each
subject was then given a meal of normal composition (40% fat
(polyunsatured/satured, 0.5), 45% carbohydrate, 15% protein,
energy fractions, approximately) and 5 ml blood was drawn at
two hours after the beginning of the meal. The blood was
centrifuged at 4000 g, 4 °C for 15 minutes, and stored at - 70 °C
until all the samples were available, so that all the analyses
were done in the same assay run. . ,
Analytical imprecision
Within-run imprecision was determined by 20 replicate meas-
urements of three different serum samples .with different con-
centrations of lipoprotein(a) on the same plate in one assay.
Between-run imprecision was determined from data on 20 meas-
urements on the same serum samples; between each experiment,
the sera were stored as separate samples at —70 °C.
Biological variabi l i ty
The biological variation of lipoprotein(a) was determined by
taking five 10-ml blood specimens from each of 8 apparently
healthy normolipidaemic laboratory workers (4 men and 4
women, ages 21 to 45 years) once a week for five weeks. The
inclusion criteria were that the subjects be within 20% of ideal
body weight, and, for women, have regular menstrual cycles
and use a non-hormonal contraceptive method. The design and
execution of the experiment were thoroughly explained to the
subjects and informed consent was obtained. They were urged
not to change their dietary habits or activities, and their weights
during the study remained stable within ± 1.0 kg. After fasting
for 12 to 14 hours and without any morning exercises or
smoking, venous blood was obtained in a sitting position for 1
to 5 minutes with minimal stasis by the same phlebotomist
between 8 and 9 a. m. Serum specimens, separated by centrif-
ugation (4000 g, 15 minutes), were stored at ^70°C until
analysed. When all the specimens were available, they were
thawed, mixed, and centrifuged to ensure clarity and assayed
in a single run in duplicate in random order. To further minimize
analytical variation, a single analyst performed all the assays
and a single lot of reagents was used.
Biological within-subject variance was estimated from the total
within-subject variance minus within-run analytical variance
(7). The latter was estimated from the replicate analyses of the
specimens from the patients themselves (11). Biological be-
tween-subject variance was estimated from the total variance
of the set of duplicate data from the assay performed on each
subject minus analytical and within-subject components (7). All
the components of variation were then transformed to the
relevant coefficients of variation using the overall mean (7).
Results and Discussion
Effect of anticoagulant
The anticoagulants can cause various degrees of shifts
of water from the blood cells into the plasma and
thus alter the plasma concentrations of the large par-
ticle constituents, like lipoprotein(a),-(12). However,
serum and plasma EDTA specimens collected from
the same subjects gave similar results (median value
(and range), 57 (7-774) vs 58 (2-850) mg/1, paired
sample Wilcoxon test, p = 0.74). Thus, lipoprotein(a)
can be measured in either plaSma EDTA or serum
with no significant differences.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No, 1
Panteghini and Pagani: Lipoprotein(a) variability 25
Tab. 1. Serum concentrations and isoform patterns of lipoprotein(a) before and after storage at —20 °C.
Lipoprotein(a) phenotype
Storage time, months
0 3
*: mean ± SD, n = 4
Lipoprotein(a) concentration, mg/1
Storage time, months
0 1
S2
S2/S3
S3
S4
S2
S2/S3
S3
S4
1539 ± 21*
339 + 6
179 + 8
27+ 1
1533 ± 140
340 + 15
170 + 6
29 + 1
1489 ± 61
333 + 5
190 + 2
31 ± 1
1551 + 43
331 ± 21
164+ 8
25 ± 3
Effect of storage
It is known that sample handling and storage may
drastically influence the accuracy of the results in
many kinds of lipoprotein assay (13). The effect of
storage on serum lipoprotein(a) concentration and
isoform pattern is showed in figure 1 and table 1. In
agreement with the preliminary results of Fless et al.
(14), we observed no significant variations in lipopro-
tein(a) concentration after serum was stored at 4 °C
for 15 days or at — 20 °C for three months. Further-
more, we found that serum specimens stored at
— 20 °C for as long as three months were also suitable
for lipoprotein(a) phenotyping. Consequently, analy-
ses for lipoprotein(a) should preferably be performed
on "fresh" specimens, but when analyses must be
delayed, the serum or plasma specimens may be stored
(capped) in the refrigerator up to two weeks or at
— 20 °C for a longer period.
—-·-*
15 20 25 30 35 50 70 90
Time of storage [d]
Fig. 1. Stability of lipoprotein(a) concentration in serum when
stored at 4°C (β-·) and at -20°C (n o). Values
represent the mean percent recovery ± SD of four dif-
ferent determinations.
Effect of fasting
In agreement with recent data by Pfaffinger et al.
(15), there were no significant differences between the
lipoprotein(a) concentrations of fasting serum and
postprandial serum (median value (and range), 86
(2—418) vs 86 (2 — 556) mg/1, paired samples Wil-
coxon test, p = 0.89). Thus, fasting is desirable before
a test specimen is collected for a battery of lipids and
lipoproteins, but is not essential before lipoprotein(a)
is determined.
Analytical imprecision
Results of imprecision studies are shown in table 2.
The coefficients of variations for intra- and inter-
assay imprecision ranged between 5.4 and 15.7% for
the samples we tested.
Tab. 2. Analytical imprecision of lipoprotein(a) determination
in patient samples.
Within-run imprecision
(n = 20)
Between-run imprecision
(n = 20)
χ
(mg/1)
95
299
660
SD
(mg/1)
10
34
36
CV
(%)
10.5
11.4
5.4
X
(mg/1)
108
279
645
SD
(mg/1)
17
32
47
CV
(%)
15.7
11.5
7.3
Biological variability
Table 3 shows the components of biological variation,
expressed as coefficients of variation (CV), and certain
indices derived from the data on biological variation,
namely, the analytical goal, the index of individuality,
the critical difference required for serial results from
an individual to have changed significantly at
p < 0.05, and the number of specimens which should
be collected to estimate the homeostatic value for an
individual to within + 5%. Generally, serum lipopro-
teih(a) concentration showed larger intra- and inter-
individual fluctuations than other lipids and lipopro-
teins, with the exception of the within-subject biolog-
Tab. 3. Overall mean value, components of biological varia-
tion, and derived indices for serum lipoprotein(a) con-
centration.
Mean of all results 140 mg/1
Within-subject variation (CVt) 8.5%
Between-subject variation (CVG) 85.8%
Analytical goal <4.3%
Index of individuality 0.1
Critical difference 36.3%
Number of specimens required to estimate 26
the individual's homeostatic value
to within ± 5%
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ical variation of triacylglycerols (reported values,
18.2% to 21.1%) (16, 17). Unlike the within-subject
biological variation, which represents the random
fluctuation around an individual's own homeostatic
value, the interperson biological variation for lipids
and lipoproteins primarily includes differences caused
by age, sex, and genetics (4). Population studies of
changes in lipoprotein(a) concentration with age and
sex indicate that women tend to have higher lipopro-
tein(a) values than men only after age 45 (18). There-
fore, the high value of between-subject variation for
lipoprotein(a) is mainly genetically based. On the
other hand, the existence of a genetic size polymor-
phism of apolipoprotein(a), the typical protein com-
ponent of lipoprotein(a), and of a strong inverse re-
lationship between the apparent molecular mass of
apolipoprotein(a) isoforms and plasma concentra-
tions of lipoprotein(a) are well known (19). In view
of the large inter-individual differences in lipopro-
tein(a) concentrations in serum, with values ranging
virtually from zero to well over 1000 mg/1, a total of
eight individuals, although with a wide range of lipo-
protein(a) concentrations (7 to 306 mg/1), is perhaps
too small to be representative of the population at
large and could lead to an underestimation of the true
value of between-subject variation. However, the
value obtained for between-subject variability in our
study was already much elevated, i.e., about two- to
threefold the published between-subject variability of
triacylglycerols (17), thus well expressing the marked
heterogeneity of this lipoprotein.
Numerical data on biological variation have impor-
tant applications. Analytical goals are currently best
derived from these data (5). The widely accepted
statistical postulate of Harris (20) states that maxi-
mum allowable analytical imprecision should be less
than or equal to one-half of the within-subject bio-
logical variation, i.e., about 4.3% for lipoprotein(a)
from our findings. The validity of this approach is
supported by the marked constancy of biological vari-
ation data over time, between different sizes of subject
group, and between subject groups from a variety of
countries (21). Data for analytical imprecision in table
2 show that in practice the analytical goal for lipo-
protein(a) is not achieved. Therefore, improvement in
the measurement of lipoprotein(a) is required if this
assay is to be offered by the routine laboratory.
The ratio of within-subject to between-subject biolog-
ical variability provides information on the utility of
conventional population-based reference intervals (6).
If this index of individuality is low, < 0.6, then the
use of reference intervals is of little value and may be
misleading. If the index is greater than 1.4, then the
reference intervals are of significant utility (22). For
lipoprotein(a), this index is 0.1; the reference interval
is therefore of little use in the interpretation of results
of the assay of this analyte. This justifies the attempt
to adopt cut-off points based on relative risk of cor-
onary artery disease, although
 f the setting of such
criteria is very difficult (23, 24). After all, an approach
similar to that of plasma cholesterol is undoubtedly
required for lipoprotein(a) and it is considered that
the desire to establish a reference interval is a waste
of valuable and scarce resources (25).
The results of biological in addition to analytical
variation are also used for the critical evaluation of
the significance of changes in results obtained from
analyses of serial specimens (7). In other words, to
interpret serial results objectively it is necessary to
know the change which must occur before significance
can be claimed. This "critical" difference depends on
both analytical and within-subject variability and, at
p ^ 0.05, is 2.77(CVi + CV?)1'2, where CVA is the
analytical coefficient of variation and CVi is the
within-subject biological coefficient of variation (26).
The critical difference for lipoprotein(a) at the cut-off
point of 300 mg/1, considered by some authors the
best discrimination value for risk of coronary artery
disease (23, 24), was about 35%. Thus, serial results
for lipoproteiii(a) for a single subject (if performed
with the method in this study) must change more than
35% before significance can be claimed.
In many clinical studies on lipoprotein(a), only one
specimen was collected from each subject, and the
analytical results were then used to evaluate the test
and investigate the relationships between variables.
However, a result from the analysis of a single patient
specimen should be interpreted as a lipoprotein(a)
concentration lying within certain limits. These limits
are dependent on the analytical variation of the
method used and also on the intra-individual biolog-
ical variation, and they can be calculated as the result
obtained ± 1.96(CVi + CV?)1'2 % (95% confidence
limits) (27). Repeated specimens can reduce these lim-
its. In particular, the effective variability falls by the
square root of the number of measurements
L96(CVi CV?)1
(6, 7). From the data obtained in this study, it is
therefore possible to estimate the number of speci-
mens required to determine an individual's homeo-
static value within, e.g., ±5%. With an average
analytical coefficient of variation of 10%, the number
of specimens required for lipoprotein(a) is 26.
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If population screening were introduced, it would be
necessary to critically assess the current procedures
for the interpretation of results. For example, a result
of 330 mg/1 has 95% confidence limits of 245-415
mg/1 and could be either in the high risk (415) or in
the low risk category (245) using the recommended
cut-off point of 300 mg/1 (28). However, repeated
specimen collection and analysis can reduce the con-
fidence limits of the result. In particular, for a mean
lipoprotein(a) of 330 mg/1 eight specimens would be
required to establish that the individual has a lipo-
protein(a) value greater than 300 mg/1. According to
Ford (27), this concept can be developed further since
there comes a point where the lipoprotein(a) concen-
tration is such that an individual is clearly in the high
or in the low risk group. At the 300 mg/1 cut-off point,
an observed lipoprotein(a) concentration of greater
than 405 mg/1 has 95% confidence that the true value
is greater than 300 mg/1, and an observed concentra-
tion of lower than 238 mg/1 has 95% confidence that
the true value is lower than 300 mg/1. It would there-
fore be acceptable to measure lipoprotein(a) on only
one specimen if a value of > 405 mg/1 or < 238 mg/1
is obtained because this can be clearly distinguished
from a lipoprotein(a) value of 300 mg/1. However, it
should be clear that if population screening for the
assessment of risk for coronary artery disease were
based on the measurement of lipoprotein(a), it would
be necessary to analyse multiple specimens from a
significant number of patients, thereby increasing the
cost of the screening programme.
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